The future of non-opioid drug development, such as prospective expansion of suzetrigine’s indications for Persistent pain, might hinge around the Trump administration’s method of health-related innovation. Suzetrigine’s acceptance is critical not Simply because it provides an alternative to opioids, but since it signifies a different course